Wedbush Forecasts Strong Price Appreciation for Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics (NASDAQ:ARTV) had its price objective upped by equities research analysts at Wedbush from $18.00 to $23.00 in a report issued on Friday, Marketbeat reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price objective indicates a potential upside of 282.70% from the stock’s previous close.

Several other equities analysts also recently issued reports on ARTV. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Artiva Biotherapeutics in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Artiva Biotherapeutics Trading Up 117.0%

Artiva Biotherapeutics stock opened at $6.01 on Friday. The stock has a 50-day moving average price of $2.91 and a two-hundred day moving average price of $2.44. Artiva Biotherapeutics has a 12 month low of $1.47 and a 12 month high of $15.49.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.03). As a group, equities analysts predict that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $6.00, for a total transaction of $153,000.00. Following the completion of the sale, the chief executive officer directly owned 356,721 shares in the company, valued at approximately $2,140,326. This trade represents a 6.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 21.40% of the company’s stock.

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Ground Swell Capital LLC acquired a new stake in Artiva Biotherapeutics during the second quarter worth approximately $38,000. Y Intercept Hong Kong Ltd acquired a new position in Artiva Biotherapeutics in the second quarter valued at approximately $48,000. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $53,000. Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $58,000. Finally, Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.